350 related articles for article (PubMed ID: 23045237)
21. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
Bajwa HM; Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Witt AH; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
Mult Scler Relat Disord; 2022 Apr; 60():103729. PubMed ID: 35334278
[TBL] [Abstract][Full Text] [Related]
22. Experimental laboratory biomarkers in multiple sclerosis.
Arneth B; Kraus J
Wien Med Wochenschr; 2022 Nov; 172(15-16):346-358. PubMed ID: 35254566
[TBL] [Abstract][Full Text] [Related]
23. Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
Boldrini VO; Marques AM; Quintiliano RPS; Moraes AS; Stella CRAV; Longhini ALF; Santos I; Andrade M; Ferrari B; Damasceno A; Carneiro RPD; Brandão CO; Farias AS; Santos LMB
Front Immunol; 2022; 13():750660. PubMed ID: 35197967
[TBL] [Abstract][Full Text] [Related]
24. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
Conte WL
Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
[TBL] [Abstract][Full Text] [Related]
25. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
26. Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process.
Damianidou O; Theotokis P; Grigoriadis N; Petratos S
Int J Med Sci; 2022; 19(1):164-174. PubMed ID: 34975310
[TBL] [Abstract][Full Text] [Related]
27. Adipokines as Immune Cell Modulators in Multiple Sclerosis.
Rijnsburger M; Djuric N; Mulder IA; de Vries HE
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639186
[TBL] [Abstract][Full Text] [Related]
28. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies.
Cencioni MT; Mattoscio M; Magliozzi R; Bar-Or A; Muraro PA
Nat Rev Neurol; 2021 Jul; 17(7):399-414. PubMed ID: 34075251
[TBL] [Abstract][Full Text] [Related]
29. Suppression of neuroinflammation by an allosteric agonist and positive allosteric modulator of the α7 nicotinic acetylcholine receptor GAT107.
Mizrachi T; Marsha O; Brusin K; Ben-David Y; Thakur GA; Vaknin-Dembinsky A; Treinin M; Brenner T
J Neuroinflammation; 2021 Apr; 18(1):99. PubMed ID: 33902624
[TBL] [Abstract][Full Text] [Related]
30. m6A RNA Methylation in Systemic Autoimmune Diseases-A New Target for Epigenetic-Based Therapy?
Wardowska A
Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33807762
[TBL] [Abstract][Full Text] [Related]
31. Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG; Sgarlata E; Arena S; Toscano S; Luca M; Patti F
J Neurol; 2022 Jan; 269(1):159-183. PubMed ID: 33416999
[TBL] [Abstract][Full Text] [Related]
32. Anti-Kir4.1 Antibodies in Multiple Sclerosis: Specificity and Pathogenicity.
Imamura M; Higuchi O; Maeda Y; Mukaino A; Ueda M; Matsuo H; Nakane S
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348803
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
[TBL] [Abstract][Full Text] [Related]
34. The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.
Zhong M; van der Walt A; Campagna MP; Stankovich J; Butzkueven H; Jokubaitis V
Neurotherapeutics; 2020 Oct; 17(4):1768-1784. PubMed ID: 33058021
[TBL] [Abstract][Full Text] [Related]
35. Antibodies and Immunity During Kawasaki Disease.
Hicar MD
Front Cardiovasc Med; 2020; 7():94. PubMed ID: 32671098
[TBL] [Abstract][Full Text] [Related]
36. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
37. Novel B cell-dependent multiple sclerosis model using extracellular domains of myelin proteolipid protein.
Boyden AW; Brate AA; Karandikar NJ
Sci Rep; 2020 Mar; 10(1):5011. PubMed ID: 32193439
[TBL] [Abstract][Full Text] [Related]
38. Antibody signatures in patients with histopathologically defined multiple sclerosis patterns.
Stork L; Ellenberger D; Ruprecht K; Reindl M; Beißbarth T; Friede T; Kümpfel T; Gerdes LA; Gloth M; Liman T; Paul F; Brück W; Metz I
Acta Neuropathol; 2020 Mar; 139(3):547-564. PubMed ID: 31950335
[TBL] [Abstract][Full Text] [Related]
39. Aberrant DNA methylation profile exacerbates inflammation and neurodegeneration in multiple sclerosis patients.
Celarain N; Tomas-Roig J
J Neuroinflammation; 2020 Jan; 17(1):21. PubMed ID: 31937331
[TBL] [Abstract][Full Text] [Related]
40. APRIL and BAFF: novel biomarkers for central nervous system lymphoma.
Mulazzani M; Huber M; Borchard S; Langer S; Angele B; Schuh E; Meinl E; Dreyling M; Birnbaum T; Straube A; Koedel U; von Baumgarten L
J Hematol Oncol; 2019 Oct; 12(1):102. PubMed ID: 31615554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
